Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

The Associated Press April 19, 2010, 2:52PM ET

Lannett gets FDA approval for generic Zofran

Lannett Co. said Friday it received Food and Drug Administration approval for a generic version of GlaxoSmithKline's Zofran.

The drug is used as a treatment for nausea caused by chemotherapy and to prevent postoperative nausea. It had sales of about $58 million in 2009, Lannett said.

Lannett did not disclose a launch date for the generic version in a statement.

Shares of Lannett rose 35 cents, or 7.2 percent, to $5.24 in afternoon trading. The stock has traded between $4.10 and $9.74 over the last 52 weeks.

Glaxo shares slid 30 cents to $39.27.


BW Mall - Sponsored Links

Buy a link now!